Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic

NCT04565509 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1143

Last updated 2026-02-23

Study results available
· View outcomes & findings →

Summary

The primary goal of this project is to identify the best messaging and implementation strategies to maximize SARS-CoV-2 testing for children with intellectual and developmental disabilities (IDD) and their teachers to help ensure a safe school environment. Additionally, we will understand nationally the perceptions of COVID-19 and identify facilitators and barriers to help with the adoption of testing in other parts of the US and the necessary strategies to address other mitigation strategies including vaccination.

Conditions

  • Covid19
  • Intellectual Disability
  • Developmental Disability
  • Child Development Disorder

Interventions

BEHAVIORAL

Standard Messaging

A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.

BEHAVIORAL

Enhanced Messaging

A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.

DIAGNOSTIC_TEST

COVID-19 Testing

Weekly surveillance COVID-19 testing.

BEHAVIORAL

Focus Groups

Focus groups to develop enhanced messaging.

BEHAVIORAL

Fuzzy Cognitive Mapping

FCMs to assess facilitators and barriers to COVID-19 testing.

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH
  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Jason G. Newland, MD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2024-03-29
Completion
2024-03-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04565509 on ClinicalTrials.gov